-The Times of India The new Central Drug Standards Control Organisation (CDSCO) guidelines meant to help calculate compensation in case of clinical trial related injury or death in a fair and equitable manner seem to be loaded against the very people it is meant to help. The guidelines suggest a formula based on the income of the injured or dead person along with age and severity of disease. Such a formula raises...
More »SEARCH RESULT
Total Matching Records found : 105
HC Directs Seed Making Co to Compensate Farmers
-Outlook The Bombay High Court has asked a seed manufacturing company to pay compensation of Rs 45 lakh to 164 farmers in Maharashtra for supplying defective seeds as a result of which the crop quality suffered. The high court ordered the compensation while upholding an order of the Controller and Director of Agriculture which asked bayer Bio Science Pvt Ltd to pay the compensation. The company had challenged the order before the appellate...
More »IPAB dismisses bayer's stay plea in Nexavar case
-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...
More »Patients lose out to patents & profits -Deepa Kurup
-The Hindu A 2012 WHO study ranks India third — behind Myanmar and Bangladesh — among countries that fail to provide health cover to people. A 2011 study reported in The Lancet on ‘Healthcare and equity’ confirms this: every year, at least 39 million people here fall into poverty due to private out-of-pocket health expenditure. A vast majority of Indians do not have access to healthcare or essential drugs. By the...
More »Natco targets drugs ripe for compulsory licensing-Viswanath Pilla
-Live Mint Natco Pharma Ltd, which has started selling a generic version of bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...
More »
